Background
==========

Breast cancer (BC) is the most common malignant tumor for women worldwide \[[@b1-medscimonit-21-2986]\]. Similar to other cancer types, genetic factors play a central role in the development and progression of breast cancer \[[@b2-medscimonit-21-2986]\]. Studies show that excessive estrogen from the exogenous source can have pathological consequences in human cell, and result in the alteration of tumors, including the occurrence of breast cancer \[[@b3-medscimonit-21-2986]\]. Two major types of estrogen receptors (ESRs), named as ESR1 and ESR2, act as the key regulators in controlling the actions of estrogen. The ESR1 gene encodes a transcription factor with an estrogen-binding domain, an activation domain, and an estrogen response element (ERE) DNA-binding domain. By regulating the cell proliferation and differentiation via paracrine mechanism, ESR1 is believed to be tightly associated with breast cancer \[[@b4-medscimonit-21-2986]\]. Therefore, genetic variations in the ESR1 gene, which can lead to disordered estrogen activity, become a potential risk for breast cancer. Single-nucleotide polymorphisms (SNPs) of ESR1 have been studied in numerous clinical studies. Many association studies on this gene have been confined to 2 SNPs (originally detected with the restriction enzymes PvuII and XbaI \[[@b5-medscimonit-21-2986]\]), which are located in the first intron of ESR1. The ESR1 PvuII and XbaI polymorphisms have been associated to tumorigenesis and many other diseases \[[@b6-medscimonit-21-2986]\], involving heterogeneous conclusions. The meta-analysis conducted by Li et al. concluded that the PvuII polymorphism of ESR1 was a risk factor for prostate cancer development \[[@b7-medscimonit-21-2986]\], while the meta-analysis conducted by Gu et al. found no association between frequencies of the PvuII (C\>T) polymorphism and prostate cancer susceptibility, but found a positive correlation between XbaI (A\>G) polymorphism and the risk of prostate cancer \[[@b8-medscimonit-21-2986]\]. A recent study showed that the ESR1 PvuII CC/CT and XbaI GG/GA genotypes could increase susceptibility to systemic lupus erythematosus (SLE) \[[@b9-medscimonit-21-2986]\]. Several other meta-analyses suggested that the PvuII variant, instead of XbaI, was negatively associated with Alzheimer's disease (AD) in white populations, especially in southern European people, but not in Asian populations \[[@b7-medscimonit-21-2986],[@b10-medscimonit-21-2986]\]. The risk of idiopathic scoliosis was not obviously associated with the ESR1 PvuII or XbaI polymorphism \[[@b11-medscimonit-21-2986]\]. It has been also frequently reported that the PvuII and XbaI polymorphisms of the ESR1 gene are related to breast cancer \[[@b12-medscimonit-21-2986],[@b13-medscimonit-21-2986]\]. Li and Xu reported that ESR1 PvuII (C\>T) polymorphism placed pre-menopausal women at risk for breast cancer, but XbaI (A\>G) polymorphism is not associated with the risk of breast cancer \[[@b14-medscimonit-21-2986]\]. P325P polymorphism in the exon 4 of ESR1 gene has been found to be associated with bone mineral density in post-menopausal women \[[@b15-medscimonit-21-2986]\]. Korean women carrying both the ESR1 P325P CC and CDK7 Ex2-28C\>T (rs2972388) TT genotypes have been shown to be at increased breast cancer risk \[[@b16-medscimonit-21-2986]\]. However, because of the heterogeneous of data sources and analysis methods, the conclusions in many of these studies were inconsistent and controversial. Although 2 studies have been conducted on this issue, both of them have some drawbacks. Specifically, Li et al. narrowed the population to Asian women \[[@b14-medscimonit-21-2986]\]. Hu et al. focused on some of SNPs in ESR1, but SNPs like P325P, which is also associated with the risk of breast cancer, was not included in their articles \[[@b17-medscimonit-21-2986]\]. In this study, we performed an updated meta-analysis by involving as many data as possible from published studies, to provide a more precise estimation of the potential association between ESR1 PvuII, XbaI, and P325P polymorphisms and the risk of breast cancer. We collected all related studies from online databases to assess the association between 3 SNPs on ESR1 and breast cancer susceptibility. In addition, the analyses were conducted for the entire population, as well as for different subgroups using diverse population categorization strategies.

Material and Methods
====================

Search strategy
---------------

We performed an online search of PubMed, Elsevier, Science Direct, Karger, Web of Science, Wiley Online Library, and Springer databases for eligible studies on the association between ESR1 PvuII, XbaI, and P325P polymorphisms with breast cancer susceptibility. The related terms, including"ESR1", "rs2234693", "rs9340799", "rs1801132", "polymorphism","breast cancer" and "BC" were used for searching. The literature search was updated on September 2014.

Data collection
---------------

A total of 91 results were found in the literature search. Among these studies, only ones which meet the following criteria were included in our meta-analysis: (i) case-control study that focused on breast cancer and ESR1 gene polymorphisms; (ii) ethnicity and source information was available for case and control; (iii) the diagnosis of breast cancer was confirmed by pathological or histological examination; (v) were published in English language. Studies were excluded when they were: (i) irrelevant articles, duplicated articles; (ii) not case-control study; (iii) genotype frequency information was not accessible; and (iv) meta-analysis, letters, reviews, or editorial articles. As a result, 25 articles were eventually included in the meta-analysis. In our data collection procedure we restricted the time frame from Jan. 2000 to Sept. 2014. Since there was no eligible study prior to 2003, all included studies were published later than 2003. For each article, the following data were collected: the first author's last name, year of publication, country of origin, ethnicity, source of controls, and the number and frequency of ESR1 PvuII, XbaI, and P325P polymorphisms of cases or controls.

Statistical methods
-------------------

We used STATA software (version 12.0) for all analyses. The strength of the association between ESR1 polymorphisms and breast cancer susceptibility was assessed using all databases by pooled odds ratios (ORs) with 95% confidence intervals (CIs). Three models were used to evaluate the association: dominant model, recessive model, and homozygote comparison model. We also performed subgroup analyses by ethnicity (white or Asian) and source of controls (hospital-based or population-based). The heterogeneity assumption was assessed by I^2^ index. Higher I^2^ indicates more significant heterogeneity. I^2^=50% represents the dividing point between low and high heterogeneity. When I^2^≤50%, we assumed that there was no significant heterogeneity between pooled data. Correspondingly, I^2^\>50 was treated as significant heterogeneity. Moreover, based on the I^2^ index, we chose a different model in analysis: Mantel-Haenszel (M-H) fixed-effects model was used to analyze datasets without significant heterogeneity and DerSimonian and Laird (D-L) random-effects model was used to analyze datasets showing obvious heterogeneity. In our meta-analysis, we used M-H fixed-effects model to test the heterogeneity first, and then chose different models based on the testing results. ORs were calculated with each model within 95% confidence intervals. Forest plots were generated to summarize the results. Potential publication bias was assessed by the Begg's funnel plots and the Egger's test. All reported P values were for a two-tailed test.

Results
=======

We performed an online search of multiple databases for eligible studies on the association between ESR1 polymorphisms and breast cancer susceptibility. The procedure of article collection is shown in [Figure 1](#f1-medscimonit-21-2986){ref-type="fig"}. By excluding irrelevant articles, duplicated articles, and articles not focused on ESR1 polymorphisms and breast cancer, we found a total of 25 case-control studies covering 24 740 cases, and 38 866 controls were eligible \[[@b12-medscimonit-21-2986],[@b13-medscimonit-21-2986],[@b16-medscimonit-21-2986]--[@b38-medscimonit-21-2986]\], main characteristics of which are shown in [Table 1](#t1-medscimonit-21-2986){ref-type="table"}. For the ethnicity distribution, there were 8 studies of Asians and 15 studies of whites. For the source of controls, 14 studies used population-based controls and 11 studies used hospital-based controls.

To choose a proper model for the study, we first used the I^2^ indexes to evaluate the heterogeneity of the data for all 3 SNPs. As shown in [Table 2](#t2-medscimonit-21-2986){ref-type="table"}, for PvuII, the I^2^ indexes ranged from 36% to 48%, and for XbaI and P325P, the I^2^ values were mostly equal to 0% in all 3 tested genetic models. Statistically significant heterogeneities were only observed for PvuII in dominant model TT *vs.* (TC+CC) and homozygote model (TT *vs.* CC). The PvuII polymorphism showed a relative higher I^2^ index than the other 2 SNPs mainly because more studies were included in the PvuII analysis. Nevertheless, all of the I^2^ indexes were smaller than 50%, which can be still considered as non-significant heterogeneity. Therefore, the statistical power was still acceptable in our study. Since the I^2^ indexes were smaller than 50%, M-H fixed-effects models were used for all of the 3 SNPs. The forest plots for PvuII, XbaI, and P325P are shown in [Figures 2](#f2-medscimonit-21-2986){ref-type="fig"}[](#f3-medscimonit-21-2986){ref-type="fig"}--[4](#f4-medscimonit-21-2986){ref-type="fig"}, respectively. Overall, we found significant associations between ESR1 PvuII polymorphism and breast cancer susceptibility in both recessive model ((TT+TC) *vs.* CC: OR=1.08, 95% CI (1.02--1.14), p=0.01, [Figure 2B](#f2-medscimonit-21-2986){ref-type="fig"}) and homozygote model (TT *vs.* CC: OR=1.10, 95% CI (1.03--1.18), p=0.03, [Figure 2C](#f2-medscimonit-21-2986){ref-type="fig"}), but not in dominant model (TT *vs.* (TC+CC): OR=1.05, 95% CI (1.00--1.10), p=0.05, [Figure 2A](#f2-medscimonit-21-2986){ref-type="fig"}). These results indicated that the people with TT or TC genotype were at a greater risk of developing breast cancer than those with CC genotype in the ESR1 PvuII polymorphism. On the other hand, for XbaI and P325P, no significance was found for all 3 models (GG *vs.* GA+AA: OR=1.05, 95% CI (0.94--1.18), p=0.37, [Figure 3A](#f3-medscimonit-21-2986){ref-type="fig"}; GG+GA *vs.* AA: OR=1.05, 95% CI (0.98--1.12), p=0.15, [Figure 3B](#f3-medscimonit-21-2986){ref-type="fig"}; GG *vs.* AA: OR=1.08, 95% CI (0.96--1.21), p=0.22, [Figure 3C](#f3-medscimonit-21-2986){ref-type="fig"}; CC *vs.* CG+GG: OR=1.01, 95% CI (0.91--1.11), p=0.90, [Figure 4A](#f4-medscimonit-21-2986){ref-type="fig"}; CC+CG *vs.* GG: OR=0.97, 95% CI (0.86--1.09), p=0.60, [Figure 4B](#f4-medscimonit-21-2986){ref-type="fig"}; CC *vs.* GG: OR=0.96, 95% CI (0.84--1.10), p=0.56, [Figure 4C](#f4-medscimonit-21-2986){ref-type="fig"}). We found that there was no significant publication bias based on funnel plot for all 3 SNPs ([Figures 5](#f5-medscimonit-21-2986){ref-type="fig"}[](#f6-medscimonit-21-2986){ref-type="fig"}--[7](#f7-medscimonit-21-2986){ref-type="fig"}). Egger's and Begg's tests also indicated that there was no obvious bias for publications investigating the relationship of ESR1 polymorphisms with breast cancer risk, as shown in [Table 2](#t2-medscimonit-21-2986){ref-type="table"}.

Furthermore, we performed subgroup analysis, and results are shown in [Tables 3](#t3-medscimonit-21-2986){ref-type="table"}[](#t4-medscimonit-21-2986){ref-type="table"}--[5](#t5-medscimonit-21-2986){ref-type="table"}. For the subgroup analysis by ethnicity, the I^2^ indexes for PvuII were larger than 50% in both dominant model and homozygote model for white subgroups, indicating a high heterogeneity in these 2 genetic models ([Table 3](#t3-medscimonit-21-2986){ref-type="table"}). Correspondingly, we used the random-effects model for assessing the association in these high-heterogeneity cases, and used the fixed-effects model in other cases. Although the above analysis showed that TT genotype of PvuII had higher risk of breast cancer than CC genotype in all populations, further subgroup assessment demonstrated that only Asians followed this trend (TT *vs.* CC: OR=1.18, 95% CI (1.04--1.33), p=0.01), while whites did not (TT *vs.* CC: OR=1.13, 95% CI (0.98--1.29), p=0.09). For the source-stratified subgroup analysis, significant association was observed in the recessive model of hospital-based subgroup (TT+TC *vs.* CC: OR=1.15, 95% CI (1.03--1.28), p=0.02), suggesting that the people with TT + TC genotype were at a greater risk of developing breast cancer than those with CC genotype in the hospital-based subgroup. On the other hand, similar with the results obtained by using the entire population, analysis on XbaI ([Table 4](#t4-medscimonit-21-2986){ref-type="table"}) and P325P polymorphisms ([Table 5](#t5-medscimonit-21-2986){ref-type="table"}) showed that there was almost no heterogeneity for any of the subgroup cases, with I^2^ being equal to 0 for all tests except for XbaI in the white group. In addition, no statistical significant association was found between XbaI and P325P polymorphisms and breast cancer susceptibility in any of the subgroups. Given these results, we conclude that only TT genotype in PvuII was associated with the risk of breast cancer for Asians, and polymorphisms in the other 2 SNPs in ESR1 had little influence on breast cancer.

Discussion
==========

In recent years, the association of genetic susceptibility to cancers has drawn more and more attention to the study of polymorphisms of genes involved in tumorigenesis and other diseases. Numerous studies have been conducted to investigate the association between breast cancer susceptibility with 3 SNPs on ESR1: PvuII, XbaI, and P325P. However, because of the heterogeneous of data and methods, the conclusions in these studies are inconsistent and controversial. For example, some studies concluded that the PvuII CC and CT genotype significantly increased the risk of breast cancer \[[@b12-medscimonit-21-2986],[@b13-medscimonit-21-2986]\]. Some studies claimed that T allele of PvuII conferred a higher risk of breast cancer \[[@b18-medscimonit-21-2986],[@b24-medscimonit-21-2986],[@b32-medscimonit-21-2986]\]. Other studies showed that ESR1 PvuII polymorphism did not have any significant effect on breast cancer \[[@b19-medscimonit-21-2986],[@b21-medscimonit-21-2986],[@b25-medscimonit-21-2986],[@b27-medscimonit-21-2986],[@b28-medscimonit-21-2986]\]. Given these results, it is necessary to perform a meta-analysis to clarify this issue, which can rapidly and effectively increase sample size by combining data of association studies, thus enhancing the statistical power of analysis to estimate the genetic effects. Pooling data from different studies also has the advantage of reducing random errors. With the accumulation of the studies over the years, we performed an updated meta-analysis, by including 3 SNPs of ESR1 and by involving as many data as possible from published studies, to provide a more comprehensive and reliable estimation of the potential association correlation between ESR1 PvuII, XbaI, and P325P polymorphisms and the risk of breast cancer. In the present study, our results showed that genotype TT+TC or TT in ESR1 PvuII were significantly associated with increased breast cancer risk in overall population compared with CC genotype. The ESR1 PvuII polymorphism is intronic and possibly affects receptor function by changing ESR1 expression levels or altering its pre-mRNA splicing. Herrington et al. found that the C allele of PvuII produced a functional binding site for a transcription factor B-Myb, which resulted in significantly increasing transcription of a downstream reporter construct compared to the T allele \[[@b39-medscimonit-21-2986]\]. This indicates that CC genotype correlates with a higher ESR1 transcriptional level and may explain our observation that TT+TC or TT genotypes were associated with higher breast cancer risk than was CC genotype, but further functional studies are needed to investigate the functions of these alleles.

It is likely that the tumorigenesis of breast cancer is affected by many factors such as age, ethnicity, environment, and other variables. We therefore performed subgroup analysis based on ethnicity of samples. We found only Asians with TT genotype of ESR1 PvuII polymorphism had a higher risk of breast cancer than people with CC genotype, while whites did not show this trend. This may be attributable to genetic heterogeneity among different populations. We could not rule out the possibility of gene-gene interactions or the possibility of linkage disequilibrium between polymorphisms. Further studies of multiple polymorphisms in ESR1 \[[@b40-medscimonit-21-2986],[@b41-medscimonit-21-2986]\] or different genes or gene regulators such as microRNAs \[[@b42-medscimonit-21-2986]--[@b44-medscimonit-21-2986]\] are needed to address this question. In addition, it is also possible that differences in environment and lifestyle between different populations may affect the tumorigenesis of breast cancer.

The heterogeneity between studies could also be from the heterogeneous controls. Therefore, we also conducted a source-stratified subgroup analysis on 14 studies of population-based controls and 11 studies of hospital-based controls, and found significant association in the recessive model of the hospital-based subgroup. Interestingly, we also noticed that TT genotype of ESR1 PvuII polymorphism in the population-based subgroup decreased the risk of breast cancer more than CC genotype. The inconsistent results between different subgroups could come from the possible non-differential misclassification bias because the hospital-based controls might develop more breast cancer than healthy populations in subsequent years. For P325P, only 2 studies were included in subgroup analysis for PB. Given this small sample size, the statistical power is limited. More studies should be conducted to provide a more precise result.

Conclusions
===========

Our study provided a systematic review and updated meta-analysis of genetic association between ESR1 PvuII, XbaI and P325P polymorphisms and the risk of human breast cancer. Using 3 models (dominant model, recessive model, and homozygote comparison model), we confirmed that only PvuII polymorphism was a risk factor for breast cancer susceptibility in the overall population, but not XbaI and P325P SNPs. Moreover, our results suggest that subgroup assessment by ethnicity of samples and source of controls yields results that are different from those using the overall population. Thus, we believe our study clarifies the inconsistent conclusions from previous studies, and will shed some light on future breast cancer-related research.
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###### 

Characteristics of literatures included in the meta-analysis.

  Author            Year   Case     Control   Country   Ethnicity   Source[\*](#tfn1-medscimonit-21-2986){ref-type="table-fn"}   Age      Genotyping method   Premeno-pausal proportion                                                                  
  ----------------- ------ -------- --------- --------- ----------- ------------------------------------------------------------ -------- ------------------- --------------------------- ------------- ----------- ---- ------------- ----------------- -------
  Madeira           2014   9        49        6         64          8                                                            39       25                  72                          Brazil        Caucasian   HB   Median: 55    PCR-RFLP          Mixed
  Chattpoadhyay     2014   39       164       157       360         62                                                           162      136                 360                         India         Caucasian   PB   \<50: 44%     PCR-RFLP          49%
  Tang              2013   127      374       293       875         136                                                          375      334                 886                         China         Asian       HB   Mean: 49      MALDI-TOF         50%
  Lu                2013   57       228       227       542         137                                                          454      425                 1016                        China         Asian       PB   Mean: 49      PCR-RFLP          N/A
  Sakoda            2011   93       290       229       612         120                                                          427      327                 874                         China         Asian       PB   \<50: 51.7%   SNaPshot assays   55%
  Han               2011   107      399       353       859         151                                                          402      324                 877                         China         Asian       HB   Mean: 51      TaqMan            48%
  Sonestedt         2009   108      273       158       539         218                                                          539      316                 1073                        Sweden        Caucasian   PB   Mean: 57      SEQUENOM          N/A
  Dunning           2009   938      2164      1260      4362        934                                                          2296     1318                4548                        UK            Caucasian   PB                 PCR-RFLP          
  Ladd              2008   24       94        72        190         453                                                          1648     1602                3703                        Netherlands   Caucasian   PB   Mean: 70      N/A               0%
  Gonzalez-Mancha   2008   82       209       153       444         150                                                          361      193                 704                         Spain         Caucasian   HB   Mean: 58      PCR-RFLP          
  Wang              2007   87       188       117       392         176                                                          393      214                 783                         USA           Caucasian   PB                 PCR-MPLA          
  Kjaergaard        2007   245      613       398       1256        537                                                          1225     727                 2489                        Denmark       Caucasian   HB                 TaqMan            25%
  Hu                2007   16       58        39        113         19                                                           45       49                  113                         China         Asian       HB   \<50: 73%     PCR-RFLP          72%
  Shen              2006   29       120       98        247         43                                                           124      107                 274                         China         Asian       PB   \<50: 79%     PCR-RFLP          
  Onland-Moret      2005   69       150       89        308         96                                                           153      88                  337                         Netherlands   Caucasian   PB   Mean: 57      PCR-RFLP          
  Modugno           2005   80       115       53        248         1272                                                         1810     819                 3901                        USA           Caucasian   PB   Mean: 71      PCR-MPLA          
  Wedren            2004   268      634       390       1292        313                                                          651      384                 1348                        Sweden        Caucasian   PB   50--74        PCR--RFLP         0%
  Shin              2003   35       91        75        201         26                                                           103      61                  190                         Korea         Asian       HB                 PCR-RFLP          
  Cai               2003   138      516       415       1069        190                                                          546      430                 1166                        China         Asian       PB   Mean: 47      PCR-RFLP          64%
  **Xbal**                 **GG**   **GA**    **AA**    **Total**   **GG**                                                       **GA**   **AA**              **Total**                                                                                  
  Madeira           2014   12       47        5         64          14                                                           58       0                   72                          Brazil        Caucasian   HB   Median: 55    PCR-RFLP          Mixed
  Sakoda            2011   22       197       395       614         30                                                           277      569                 876                         China         Asian       PB   \<50: 51.7%   SNaPshot assays   55%
  Dunning           2009   521      1967      1682      4170        526                                                          2048     1873                4447                        UK            Caucasian   PB                 PCR-RFLP          
  Wang              2007   19       137       237       393         29                                                           299      461                 789                         USA           Caucasian   PB                 PCR-MPLA          
  Slattery          2007   52       235       287       574         61                                                           313      351                 725                         USA           Caucasian   PB                 PCR-RFLP          
  Shen              2006   14       84        149       247         21                                                           87       168                 276                         China         Asian       PB   \<50: 79%     PCR--RFLP         
  Cai               2003   36       497       536       1069        49                                                           507      610                 1166                        China         Asian       PB   Mean: 47      PCR-RFLP          64%
  **P325P**                **CC**   **CG**    **GG**    **Total**   **CC**                                                       **CG**   **GG**              **Total**                                                                                  
  Han               2011   208      441       216       865         232                                                          452      201                 885                         China         Asian       HB   Mean: 51      TaqMan            48%
  Ding              2010   241      468       225       934         402                                                          751      391                 1544                        China         Asian       HB                 Taqman            
  Jeon              2009   218      311       217       746         182                                                          288      185                 655                         Korea         Asian       HB   Mean: 47      MALDI-TOF         
  Sidding           2008   55       23        1         79          56                                                           27       2                   85                          Sudan         Caucasian   HB   Mean: 46      PCR-SSCP          67%
  Wang              2007   237      137       19        393         461                                                          299      29                  789                         USA           Caucasian   PB                 PCR-MPLA          
  Gallicchio        2006   52       31        7         90          794                                                          440      64                  1298                        USA           Caucasian   PB   Mean: 54      TaqMan            26.2%
  Fernandez         2006   355      156       18        529         356                                                          167      22                  545                         Spain         Caucasian   HB   \<50: 27%     Taqman            15%

HB -- hospital-based; PB -- population-based.

###### 

Meta-analysis for all population with Dominant model, Recessive model and homozygote comparison.

  Analysis model    Analysis method   Heterogeneity   OR     Publication bias                               
  ----------------- ----------------- --------------- ------ ------------------ ------ ------ ------ ------ ------
  **Pvull**                                                                                                 
   TT *vs.* TC+CC   Fixed             43.6            0.02   1.05               1.00   1.10   0.05   0.48   0.47
   TT+TC *vs.* CC   Fixed             36.8            0.06   1.08               1.02   1.14   0.01   0.94   0.15
   TT *vs.* CC      Fixed             48.1            0.01   1.10               1.03   1.18   0.03   0.68   0.62
  **Xbal**                                                                                                  
   GG *vs.* GA+AA   Fixed             3.5             0.40   1.05               0.94   1.18   0.37   0.76   0.73
   GG+GA *vs.* AA   Fixed             0.0             0.86   1.05               0.98   1.12   0.15   0.55   0.19
   GG *vs.* AA      Fixed             0.0             0.51   1.08               0.96   1.21   0.22   0.76   0.87
  **P325P**                                                                                                 
   CC *vs.* CG+GG   Fixed             0.0             0.82   1.01               0.91   1.11   0.90   0.76   0.74
   CC+CG *vs.* GG   Fixed             0.0             0.63   0.97               0.86   1.09   0.60   0.76   0.68
   CC *vs.* GG      Fixed             0.0             0.64   0.96               0.84   1.10   0.56   1.00   0.83

###### 

Subgroup meta-analysis of the association between ESR1 PvuIIpolymorphisms and breast cancer risk.

  Subgroup        TT *vs.* TC+CC   TT+TC *vs.* CC   TT *vs.* CC                                                                                             
  --------------- ---------------- ---------------- ------------------- ------ ------ ------ ------------------- ------ ------ -------- ------------------- ------
  **Ethnicity**                                                                                                                                             
   Caucasian      58.5             0.01             1.06 (0.95--1.18)   0.28   31.9   0.14   1.05 (0.98--1.12)   0.16   56.1   0.01     1.13 (0.98--1.29)   0.09
   Asian          10.0             0.35             1.05 (0.97--1.14)   0.24   38.0   0.01   1.17 (1.04--1.31)   0.12   33.8   0.16     1.18 (1.04--1.33)   0.01
  **Source**                                                                                                                                                
   HB             74.6             \<0.01           1.02 (0.83--1.26)   0.83   15.0   0.32   1.15 (1.03--1.28)   0.02   58.9   0.02     1.13 (0.90--1.43)   0.28
   PB             0.0              0.77             1.04 (0.98--1.10)   0.23   44.2   0.05   1.05 (0.99--1.12)   0.13   81.3   \<0.01   0.78 (0.64--0.94)   0.01

P-value from heterogeneity test;

P-value from OR test.

###### 

Subgroup meta-analysis of the association between ESR1 Xbalpolymorphisms and breast cancer risk.

  Subgroup        GG *vs.* GA+AA   GG+GA *vs.* AA   GG *vs.* AA                                                                                         
  --------------- ---------------- ---------------- ------------------- ------ ----- ------ ------------------- ------ ----- ------ ------------------- ------
  **Ethnicity**                                                                                                                                         
   Caucasian      11.9             0.33             1.09 (0.96--1.22)   0.17   0.0   0.51   1.04 (0.97--1.13)   0.27   0.0   0.41   1.11 (0.98--1.26)   0.10
   Asian          0.0              0.67             0.85 (0.62--1.16)   0.30   0.0   0.89   1.06 (0.94--1.20)   0.34   0.0   0.73   0.88 (0.64--1.20)   0.42
  **Source**                                                                                                                                            
   PB             0.0              0.66             1.04 (0.93--1.17)   0.46   0.0   0.76   1.05 (0.98--1.12)   0.15   0.0   0.75   1.07 (0.95--1.20)   0.27

P-value from heterogeneity test;

P-value from OR test;

Analysis on HB is not performed due to the lack of study.

###### 

Subgroup meta-analysis of the association between ESR1 P325Ppolymorphisms and breast cancer risk.

  Subgroup        CC *vs.* CG+GG   CC+CG *vs.* GG   CC *vs.* GG                                                                                         
  --------------- ---------------- ---------------- ------------------- ------ ----- ------ ------------------- ------ ----- ------ ------------------- ------
  **Ethnicity**                                                                                                                                         
   Caucasian      0.0              0.81             1.06 (0.90--1.24)   0.50   0.0   0.51   0.88 (0.60--1.29)   0.52   0.0   0.50   0.90 (0.61--1.33)   0.60
   Asian          0.0              0.51             0.98 (0.87--1.10)   0.70   0.0   0.43   0.98 (0.87--1.11)   0.73   0.0   0.42   0.97 (0.84--1.12)   0.67
  **Source**                                                                                                                                            
   HB             0.0              0.72             1.00 (0.90--1.12)   0.98   0.0   0.67   0.99 (0.88--1.11)   0.83   0.0   0.64   0.98 (0.85--1.13)   0.81
   PB             0.0              0.39             1.03 (0.83--1.27)   0.82   0.0   0.70   0.71 (0.44--1.14)   0.16   0.0   0.60   0.72 (0.44--1.18)   0.19

P-value from heterogeneity test;

P-value from OR test.
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